PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsErenumab
Aimovig(erenumab)
Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
Download report
Favorite
Novartis Pharmaceuticals
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Aimovig (discontinued: Aimovig)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Erenumab
Tradename
Proper name
Company
Number
Date
Products
Aimovigerenumab-aooeAmgenN-761077 RX2018-05-17
2 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aimovigBiologic Licensing Application2025-04-01
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N02: Analgesics
N02C: Antimigraine preparations
N02CD: Calcitonin gene-related peptide (cgrp) antagonists
N02CD01: Erenumab
HCPCS
No data
Clinical
Clinical Trials
76 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G435456121
HeadacheD006261R511214
Secondary headache disordersD05127111
Prescription drug overuseD00006749011
SinusitisD012852EFO_0007486J3211
Facial painD005157R51.911
FaciesD01906611
RhinosinusitisD00009682511
Indications Phases 3
No data
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients11
Hot flashesD01958411
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameErenumab
INNerenumab
Description
Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>6UMH:H,h|erenumab Fab heavy chain, IgG1 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLF LQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDEVD >6UMH:L,l|erenumab Fab light chain, IgG1 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQ TGDEADYYCGTWDSRLSAVVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVK AGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
Identifiers
PDB6UMG, 6UMH, 6UMI, 6UMJ
CAS-ID
RxCUI
ChEMBL IDCHEMBL3833329
ChEBI ID
PubChem CID
DrugBankDB14039
UNII IDI5I8VB78VT (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CALCRL
CALCRL
Organism
Homo sapiens
Gene name
CALCRL
Gene synonyms
CGRPR
NCBI Gene ID
Protein name
calcitonin gene-related peptide type 1 receptor
Protein synonyms
calcitonin receptor-like, Calcitonin receptor-like receptor, CGRP type 1 receptor
Uniprot ID
Mouse ortholog
Calcrl (54598)
calcitonin gene-related peptide type 1 receptor (Q9WUP2)
Variants
No data
Financial
Revenue by drug
$
£
Aimovig Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Erenumab
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,612 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
47,919 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use